171 related articles for article (PubMed ID: 21304974)
1. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
Björkelund H; Gedda L; Andersson K
PLoS One; 2011 Jan; 6(1):e16536. PubMed ID: 21304974
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
Björkelund H; Gedda L; Barta P; Malmqvist M; Andersson K
PLoS One; 2011; 6(9):e24739. PubMed ID: 21931838
[TBL] [Abstract][Full Text] [Related]
3. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Nishimura Y; Bereczky B; Ono M
Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
[TBL] [Abstract][Full Text] [Related]
4. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
[TBL] [Abstract][Full Text] [Related]
7. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Nishimura Y; Yoshioka K; Bereczky B; Itoh K
Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
[TBL] [Abstract][Full Text] [Related]
8. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Myers MV; Manning HC; Coffey RJ; Liebler DC
Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
11. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
[TBL] [Abstract][Full Text] [Related]
12. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Zhu S; Belkhiri A; El-Rifai W
Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
[TBL] [Abstract][Full Text] [Related]
13. Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Lin HQ; Katsifis A; Meriaty H
Anticancer Res; 2010 Dec; 30(12):4899-905. PubMed ID: 21187468
[TBL] [Abstract][Full Text] [Related]
14. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
[TBL] [Abstract][Full Text] [Related]
16. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Albitar L; Laidler LL; Abdallah R; Leslie KK
Mol Cancer Ther; 2005 Dec; 4(12):1891-9. PubMed ID: 16373704
[TBL] [Abstract][Full Text] [Related]
17. Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.
He P; Li G
Cancer Chemother Pharmacol; 2013 Aug; 72(2):341-8. PubMed ID: 23748900
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
von Achenbach C; Weller M; Szabo E
J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622
[TBL] [Abstract][Full Text] [Related]
19. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
[TBL] [Abstract][Full Text] [Related]
20. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
